Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 10,200 shares, a decline of 73.4% from the January 15th total of 38,400 shares. Based on an average daily trading volume, of 103,600 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the company are sold short.
Theratechnologies Stock Performance
Theratechnologies stock traded up $0.12 during mid-day trading on Friday, reaching $1.75. The company's stock had a trading volume of 390,969 shares, compared to its average volume of 79,739. Theratechnologies has a 12-month low of $1.08 and a 12-month high of $2.18. The company has a market capitalization of $80.47 million, a P/E ratio of -17.50 and a beta of 1.26. The firm's fifty day moving average price is $1.70 and its two-hundred day moving average price is $1.42.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new stake in shares of Theratechnologies in the fourth quarter worth $27,000. JPMorgan Chase & Co. purchased a new stake in shares of Theratechnologies in the fourth quarter worth $33,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Theratechnologies in the fourth quarter worth $108,000. Virtu Financial LLC purchased a new stake in shares of Theratechnologies in the fourth quarter worth $40,000. Finally, Harbour Investments Inc. increased its stake in shares of Theratechnologies by 20.0% in the fourth quarter. Harbour Investments Inc. now owns 87,772 shares of the company's stock worth $159,000 after purchasing an additional 14,655 shares in the last quarter.
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
See Also
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
